ATE238061T1 - Verwendung von zytokinen und mitogenen für inhibierung von pathologischen immunantworten - Google Patents
Verwendung von zytokinen und mitogenen für inhibierung von pathologischen immunantwortenInfo
- Publication number
- ATE238061T1 ATE238061T1 AT98957605T AT98957605T ATE238061T1 AT E238061 T1 ATE238061 T1 AT E238061T1 AT 98957605 T AT98957605 T AT 98957605T AT 98957605 T AT98957605 T AT 98957605T AT E238061 T1 ATE238061 T1 AT E238061T1
- Authority
- AT
- Austria
- Prior art keywords
- mitogens
- cytokines
- inhibition
- immune responses
- pathological immune
- Prior art date
Links
- 102000004127 Cytokines Human genes 0.000 title 1
- 108090000695 Cytokines Proteins 0.000 title 1
- 230000005764 inhibitory process Effects 0.000 title 1
- 239000003226 mitogen Substances 0.000 title 1
- 230000001575 pathological effect Effects 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 108010002350 Interleukin-2 Proteins 0.000 abstract 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 abstract 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 abstract 1
- 239000012190 activator Substances 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 230000016784 immunoglobulin production Effects 0.000 abstract 1
- 210000005087 mononuclear cell Anatomy 0.000 abstract 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 abstract 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
- A61K40/22—Immunosuppressive or immunotolerising
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/416—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/15—Transforming growth factor beta (TGF-β)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Plant Substances (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US6450797P | 1997-11-05 | 1997-11-05 | |
| PCT/US1998/023584 WO1999025366A1 (en) | 1997-11-05 | 1998-11-05 | Use of cytokines and mitogens to inhibit pathological immune responses |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE238061T1 true ATE238061T1 (de) | 2003-05-15 |
Family
ID=22056456
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT98957605T ATE238061T1 (de) | 1997-11-05 | 1998-11-05 | Verwendung von zytokinen und mitogenen für inhibierung von pathologischen immunantworten |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US6228359B1 (enExample) |
| EP (1) | EP1028738B1 (enExample) |
| JP (1) | JP4309047B2 (enExample) |
| AT (1) | ATE238061T1 (enExample) |
| AU (1) | AU747767B2 (enExample) |
| CA (1) | CA2309115C (enExample) |
| DE (1) | DE69813868T2 (enExample) |
| DK (1) | DK1028738T3 (enExample) |
| ES (1) | ES2198774T3 (enExample) |
| PT (1) | PT1028738E (enExample) |
| WO (1) | WO1999025366A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6358506B1 (en) * | 1997-11-05 | 2002-03-19 | University Of Southern California | Use of cytokines and mitogens to inhibit pathological immune responses |
| US20030157057A1 (en) * | 1999-05-05 | 2003-08-21 | Horwitz David A. | Methods for the induction of professional and cytokine-producing regulatory T cells |
| EP1061949B1 (en) | 1998-03-03 | 2009-07-15 | University of Southern California | Cytokines and mitogens to inhibit graft-versus-host disease |
| US6803036B1 (en) | 1998-03-03 | 2004-10-12 | University Of Southern California | Use of cytokines, cells and mitogens to inhibit graft versus host disease |
| ES2311462T3 (es) * | 1999-05-05 | 2009-02-16 | University Of Southern California | Uso de citocinas y mitogenos para inhibir las respuestas inmunes patologicas. |
| ATE431399T1 (de) * | 1999-09-01 | 2009-05-15 | Univ Southern California | Verwendung von cytokinen, zellen und mitogene zur hemmung der graft-versus-host krankheit |
| AU2007202534B2 (en) * | 2000-04-11 | 2011-06-09 | University Of Southern California | A method to prevent graft rejection using TGF-beta to induce T suppressor cells |
| ATE460475T1 (de) | 2000-04-11 | 2010-03-15 | Univ Southern California | Methode zur verhinderung der transplantatabstossung unter verwendung von tgf- beta zur induktion von t-suppressorzellen |
| AU2002364230B2 (en) * | 2001-12-21 | 2008-05-01 | University Of Southern California | Methods for the induction of professional and cytokine-producing regulatory cells |
| US20050202010A1 (en) * | 2003-08-29 | 2005-09-15 | Giroir Brett P. | Method of treatment and bioassay involving macrophage migration inhibitory factor (MIF) as cardiac-derived myocardial depressant factor |
| CN102971416B (zh) | 2010-04-22 | 2018-03-30 | 南加州大学 | 用于扩增和稳定天然调节性t细胞的方法和组合物 |
| EP2763692A2 (en) | 2011-10-06 | 2014-08-13 | European Molecular Biology Laboratory | Use of igf-1 in the modulation of treg cell activity and the treatment and prevention of autoimmune disorders or diseases |
| AU2012320597C1 (en) | 2011-10-07 | 2015-10-15 | Baxalta GmbH | oxMIF as a diagnostic marker |
| WO2013173076A1 (en) | 2012-05-04 | 2013-11-21 | University Of Southern California | Methods and compositions for generating and using allogeneic suppressor cells |
| GB201421716D0 (en) * | 2014-12-05 | 2015-01-21 | King S College London | Cell expansion procedure |
-
1998
- 1998-11-05 ES ES98957605T patent/ES2198774T3/es not_active Expired - Lifetime
- 1998-11-05 AU AU13827/99A patent/AU747767B2/en not_active Ceased
- 1998-11-05 AT AT98957605T patent/ATE238061T1/de active
- 1998-11-05 PT PT98957605T patent/PT1028738E/pt unknown
- 1998-11-05 CA CA2309115A patent/CA2309115C/en not_active Expired - Fee Related
- 1998-11-05 DK DK98957605T patent/DK1028738T3/da active
- 1998-11-05 DE DE69813868T patent/DE69813868T2/de not_active Expired - Lifetime
- 1998-11-05 JP JP2000520799A patent/JP4309047B2/ja not_active Expired - Fee Related
- 1998-11-05 WO PCT/US1998/023584 patent/WO1999025366A1/en not_active Ceased
- 1998-11-05 EP EP98957605A patent/EP1028738B1/en not_active Expired - Lifetime
- 1998-11-05 US US09/186,771 patent/US6228359B1/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| WO1999025366A1 (en) | 1999-05-27 |
| DE69813868T2 (de) | 2004-03-04 |
| CA2309115C (en) | 2010-10-19 |
| DE69813868D1 (de) | 2003-05-28 |
| ES2198774T3 (es) | 2004-02-01 |
| DK1028738T3 (da) | 2003-08-11 |
| AU747767B2 (en) | 2002-05-23 |
| AU1382799A (en) | 1999-06-07 |
| JP4309047B2 (ja) | 2009-08-05 |
| US6228359B1 (en) | 2001-05-08 |
| EP1028738A1 (en) | 2000-08-23 |
| PT1028738E (pt) | 2003-08-29 |
| EP1028738B1 (en) | 2003-04-23 |
| CA2309115A1 (en) | 1999-05-27 |
| JP2001523443A (ja) | 2001-11-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69813868D1 (de) | Verwendung von zytokinen und mitogenen für inhibierung von pathologischen immunantworten | |
| ES2099158T3 (es) | Tratamiento del rechazo de trasplantes o de enfermedades autoinmunitarias y complejo de la formula general x-pro-y-boropro asociada al mismo. | |
| EA199900349A1 (ru) | Каталитическая субъединица теломеразы человека | |
| ATE279181T1 (de) | Verwendung von 5ht-6 antagonisten zur behandlung adhd | |
| ATE126441T1 (de) | Pentigetide zur behandlung von nicht-ige- vermittelten entzündlichen erkrankungen. | |
| NZ294446A (en) | Stem cell proliferation inhibitors, haemoglobin chains used for the treatment of autoimmune diseases. | |
| DE69734766D1 (de) | Hemmstoff und stimulator der proliferation haematopoietischer stammzellen und deren anwendungen | |
| DE3579113D1 (de) | Zusammensetzungen zur milderung, behandlung und bestimmungung von arthritschen krankheiten und aehnlichen zustaenden. | |
| DK1112275T3 (da) | Hidtil ukendte heteroaromatiske inhibitorer for fructose-1,6-bisphosphatase | |
| AR243600A1 (es) | Un aparato para el tratamiento de muestras biologicas y microbiologicas. | |
| ATE297036T1 (de) | Verfahren und vorrichtung zum vorhersagen von menschlichen kognitiven leistung | |
| DE69633679D1 (de) | Substituierte aryl-oder heteroarylamide mit retinoid-ähnlicher biologischer aktivität | |
| DE69412377D1 (de) | Bimetallisches-Metallocene Alumoxan Katalysatorsystem und seine Verwendung für die Herstellung von elastomeren Ethylencopolymerisaten | |
| DE69435303D1 (de) | Er behandlung von krankheiten bei denen eine cytok | |
| IT8121396A0 (it) | Procedimento per il trattamento, in particolare per la rigenerazione di olio usato. | |
| DE3687097D1 (de) | Therapeutisches mittel zur behandlung haematopoietischer krankheiten. | |
| PT77019A (de) | Mittel zur behandlung von wunden | |
| ATE119395T1 (de) | Verwendung von interleukin-4 zur steigerung der neutrophilenzahl und zur behandlung von myeloid oder monocytoid leukeamie. | |
| ATE404662T1 (de) | Verwendung von zytokinen und mitogenen zur inhibierung von pathologischen immunantworten | |
| Rachman | Psychotherapy of difficult cases: Flexibility and responsiveness in contemporary practice. | |
| DE69127713D1 (de) | Behandlung von Abgasen, die Silikon- und/oder Phosphorverbindungen enthalten | |
| DE3856329D1 (de) | Verwendung von Ethisterone zur topischen Behandlung von Akne oder androgenetischer Alopezie | |
| DE69007374D1 (de) | Injektionssystem für die Behandlung von Zellen. | |
| ATE123942T1 (de) | 5-aryl-3h-1,2,4-triazol-3-one und ihre verwendung als antikonvulsiva. | |
| DE69936779D1 (de) | Verwendung von ngali nussöl zur behandlung/linderung der arthritisschmerzen und anderer ähnlichen störungen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1028738 Country of ref document: EP |